Unknown

Dataset Information

0

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.


ABSTRACT:

Introduction

Multilineage myelosuppression is an acute toxicity of cytotoxic chemotherapy, resulting in serious complications and dose modifications. Current therapies are lineage specific and administered after chemotherapy damage has occurred. Trilaciclib is a cyclin-dependent kinase 4/6 inhibitor that is administered prior to chemotherapy to preserve hematopoietic stem and progenitor cells and immune system function during chemotherapy (myelopreservation).

Methods

In this randomized, double-blind, placebo-controlled phase II trial, patients with previously treated extensive-stage small cell lung cancer (ES-SCLC) were randomized to receive intravenous trilaciclib 240 mg/m2 or placebo before topotecan 1.5 mg/m2 on days 1-5 of each 21-day cycle. Primary endpoints were duration of severe neutropenia (DSN) in cycle 1 and occurrence of severe neutropenia (SN). Additional endpoints were prespecified to further assess the effect of trilaciclib on myelopreservation, safety, patient-reported outcomes (PROs), and antitumor efficacy.

Results

Thirty-two patients received trilaciclib, and 29 patients received placebo. Compared with placebo, administration of trilaciclib prior to topotecan resulted in statistically significant and clinically meaningful decreases in DSN in cycle 1 (mean [standard deviation] 2 [3.9] versus 7 [6.2] days; adjusted one-sided P?ConclusionsCompared with placebo, the addition of trilaciclib prior to topotecan for the treatment of patients with previously treated ES-SCLC improves the patient experience of receiving chemotherapy, as demonstrated by a reduction in chemotherapy-induced myelosuppression, improved safety profile, improved quality of life and no detrimental effects on antitumor efficacy.

Trial registration

ClinicalTrials.gov: NCT02514447.

SUBMITTER: Hart LL 

PROVIDER: S-EPMC7854399 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.

Hart Lowell L LL   Ferrarotto Renata R   Andric Zoran G ZG   Beck J Thaddeus JT   Subramanian Janakiraman J   Radosavljevic Davorin Z DZ   Zaric Bojan B   Hanna Wahid T WT   Aljumaily Raid R   Owonikoko Taofeek K TK   Verhoeven Didier D   Xiao Jie J   Morris Shannon R SR   Antal Joyce M JM   Hussein Maen A MA  

Advances in therapy 20201029 1


<h4>Introduction</h4>Multilineage myelosuppression is an acute toxicity of cytotoxic chemotherapy, resulting in serious complications and dose modifications. Current therapies are lineage specific and administered after chemotherapy damage has occurred. Trilaciclib is a cyclin-dependent kinase 4/6 inhibitor that is administered prior to chemotherapy to preserve hematopoietic stem and progenitor cells and immune system function during chemotherapy (myelopreservation).<h4>Methods</h4>In this rando  ...[more]

Similar Datasets

| S-EPMC8048941 | biostudies-literature
| S-EPMC5523913 | biostudies-literature
| S-EPMC4431338 | biostudies-literature
| S-EPMC6857609 | biostudies-literature
| S-EPMC7648334 | biostudies-literature
| S-EPMC9109322 | biostudies-literature
| S-EPMC4578583 | biostudies-literature
| S-EPMC9780636 | biostudies-literature
| S-EPMC6817985 | biostudies-literature
| S-EPMC10265601 | biostudies-literature